Reno, Nevada (UroToday.com) — Lantheus Holdings, Inc. announced that its subsidiary, EXINI Diagnostics AB, has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.